Revolutionary Twice-Yearly Injection Promises to Stop HIV Transmission—Is This the End of the Epidemic?

Ever wonder what it would be like if a simple shot—just twice a year—could nearly wipe out new HIV infections? Well, buckle up, because the U.S. just gave the green light to lenacapavir, a game-changing drug from Gilead Sciences that’s poised to flip the script on HIV prevention. Now, while we’re all still holding out for that elusive vaccine, this twice-a-year wonder shot rocked two major studies by outperforming those pesky daily pills nobody remembers to take. The big question now: who exactly gets to roll up their sleeve for this revolutionary jab first, here at home and across the globe? Grab your curiosity, and let’s dive into how this medical marvel might just rewrite the future of HIV defense. LEARN MORE

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.